Capsule Summary Slidesets

Share

Program Content

Activities

  • Phase II BELLINI
    BELLINI Phase II Trial: Nivolumab + Ipilimumab in Patients With Early-Stage TNBC With Tumor-Infiltrating Lymphocytes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 12, 2022

    Expires: September 11, 2023

    View Activity
  • MONARCH 3: OS Update
    MONARCH 3 Interim OS: Abemaciclib + Nonsteroidal AI as First-line Treatment for HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2022

    Expires: September 12, 2023

    View Activity
  • TROPiCS-02: OS Update
    TROPiCS-02: OS With Sacituzumab Govitecan vs Treatment of Physician’s Choice for HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2022

    Expires: September 12, 2023

    View Activity
  • SOLO-1: 7-Yr OS
    SOLO-1: OS With 7-Yr Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 15, 2022

    Expires: September 14, 2023

    View Activity
  • CheckMate 816 Efficacy by Features
    CheckMate 816: Association of Pathologic Features With Efficacy Outcomes for Neoadjuvant Nivolumab + Platinum-Doublet CT in Resectable NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 16, 2022

    Expires: September 15, 2023

    View Activity
  • ADAURA Update
    ADAURA Trial Update: Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 19, 2022

    Expires: September 18, 2023

    View Activity
  • RELATIVITY-047: Response Results
    Phase II/III RELATIVITY-047: Additional Response Results With Nivolumab ± Relatlimab in Previously Untreated Metastatic or Unresectable Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 19, 2022

    Expires: September 18, 2023

    View Activity
  • LEAP-002: Primary Results
    LEAP-002: Placebo-Controlled Phase III Trial of Lenvatinib ± Pembrolizumab as First-line Therapy for Advanced HCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 19, 2022

    Expires: September 18, 2023

    View Activity
  • CheckMate 914: Nivo/Ipi in RCC
    CheckMate 914 (Part A): Adjuvant Nivolumab + Ipilimumab vs Placebo in Localized RCC at High Risk of Relapse Following Nephrectomy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 19, 2022

    Expires: September 18, 2023

    View Activity
  • COSMIC-313
    COSMIC-313: Phase III Study of Nivolumab + Ipilimumab ± Cabozantinib in Previously Untreated IMDC Intermediate- or Poor-Risk Advanced RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 21, 2023

    View Activity
  • CheckMate 274: Biomarker Analysis
    CheckMate 274: Exploratory Analysis of DFS According to Select Biomarkers in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma Receiving Adjuvant Nivolumab
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 21, 2023

    View Activity
  • ReFocus
    ReFocus Phase I/II Trial of RLY-4008 in Patients With FGFR Inhibitor–Naive Cholangiocarcinoma With FGFR2 Alteration
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 21, 2023

    View Activity
  • EV-103 Cohort K
    EV-103 Cohort K: Enfortumab Vedotin ± Pembrolizumab in Untreated Cisplatin-Ineligible Patients With Locally Advanced/Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 21, 2023

    View Activity
  • CodeBreaK 200
    CodeBreaK 200 Phase III Trial: Sotorasib vs Docetaxel for Patients With Previously Treated Advanced NSCLC With KRAS G12C Mutation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2022

    Expires: September 21, 2023

    View Activity
  • CheckMate 915 ctDNA Analyses
    Pretreatment ctDNA and Additional Factors Associated With Disease Recurrence in Stage IIIB-D/IV Melanoma Treated With Adjuvant Immunotherapy in CheckMate 915
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2022

    Expires: September 22, 2023

    View Activity
  • SWOG S1801
    SWOG S1801: Neoadjuvant vs Adjuvant Treatment With Pembrolizumab in Patients With Resectable Stage III-IV Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2022

    Expires: September 22, 2023

    View Activity
  • DESTINY-Lung02: Interim Analyses
    DESTINY-Lung02: Interim Results With Trastuzumab Deruxtecan (T-DXd) in Patients With Previously Treated HER2-Mutated Metastatic NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 26, 2022

    Expires: September 25, 2023

    View Activity
  • PAOLA-1 Final OS
    PAOLA-1 Phase III Trial: Final Overall Survival Results of Maintenance Olaparib + Bevacizumab in Patients With Newly Diagnosed Advanced Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 27, 2022

    Expires: September 26, 2023

    View Activity

Provided by

ProCE Banner

Supporters

AstraZeneca

Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.